Development of oral extended release formulations of 6-hydroxybuspirone-Reference-Cited by-同舟云学术

Development of oral extended release formulations of 6-hydroxybuspirone

Author:

Nicholson Sarah J.¹,Timmins Peter¹,Dockens Randy C.²,Connor Alyson³,Croop Robert⁴,Ferrie Peter¹,Zeng Jianing⁵,Dennis Andrew B.¹,Wilding Ian³

Affiliation:

1. Drug Product Science and Technology, Research and Development; Bristol-Myers Squibb; Moreton; Merseyside; CH46 1QW; UK

2. Discovery Medicine and Clinical Pharmacology, Research and Development; Bristol-Myers Squibb; Princeton; NJ; 08543; USA

3. Quotient Clinical; Ruddington; Nottingham; NG11 6JS; UK

4. Global Clinical Research, Research and Development; Bristol-Myers Squibb; Princeton; NJ; 08543; USA

5. Analytical and Bioanalytical Development, Research and Development; Bristol-Myers Squibb; Princeton; NJ; 08543; USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology,General Medicine

Reference39 articles.

1. Pharmacokinetics and disposition of 13C-buspirone HCl after intravenous and oral dosing in man;Mayol;Clin Pharmacol Ther,1985

3. Metabolism of the antianxiety drug buspirone in human subjects;Jaloo;Drug Metab Dispos,1989

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献